1. Home
  2. QTTB vs FLGC Comparison

QTTB vs FLGC Comparison

Compare QTTB & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • FLGC
  • Stock Information
  • Founded
  • QTTB 2015
  • FLGC 2019
  • Country
  • QTTB United States
  • FLGC United States
  • Employees
  • QTTB N/A
  • FLGC N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • FLGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • QTTB Health Care
  • FLGC Health Care
  • Exchange
  • QTTB Nasdaq
  • FLGC Nasdaq
  • Market Cap
  • QTTB 18.9M
  • FLGC 15.9M
  • IPO Year
  • QTTB N/A
  • FLGC 2021
  • Fundamental
  • Price
  • QTTB $1.44
  • FLGC $0.62
  • Analyst Decision
  • QTTB Hold
  • FLGC Buy
  • Analyst Count
  • QTTB 8
  • FLGC 2
  • Target Price
  • QTTB $24.00
  • FLGC $4.00
  • AVG Volume (30 Days)
  • QTTB 123.8K
  • FLGC 115.1K
  • Earning Date
  • QTTB 08-07-2025
  • FLGC 08-11-2025
  • Dividend Yield
  • QTTB N/A
  • FLGC N/A
  • EPS Growth
  • QTTB N/A
  • FLGC N/A
  • EPS
  • QTTB N/A
  • FLGC N/A
  • Revenue
  • QTTB N/A
  • FLGC $53,260,000.00
  • Revenue This Year
  • QTTB N/A
  • FLGC N/A
  • Revenue Next Year
  • QTTB N/A
  • FLGC N/A
  • P/E Ratio
  • QTTB N/A
  • FLGC N/A
  • Revenue Growth
  • QTTB N/A
  • FLGC N/A
  • 52 Week Low
  • QTTB $1.38
  • FLGC $0.42
  • 52 Week High
  • QTTB $53.79
  • FLGC $2.11
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 36.08
  • FLGC 40.12
  • Support Level
  • QTTB $1.41
  • FLGC $0.62
  • Resistance Level
  • QTTB $1.63
  • FLGC $0.64
  • Average True Range (ATR)
  • QTTB 0.11
  • FLGC 0.05
  • MACD
  • QTTB -0.02
  • FLGC -0.01
  • Stochastic Oscillator
  • QTTB 8.89
  • FLGC 7.19

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About FLGC Flora Growth Corp.

Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.

Share on Social Networks: